4. Avanir Pharmaceuticals (AVNR) acquires, develops and commercializes drugs for central nervous system disorders. Lead product candidate Zenvia for pseudobulbar affect has completed three Phase III clinical trials. Avanir's second-quarter loss widened 15% to $5.7 million, but remained steady on a per share basis, at 6 cents. Revenue declined 18%. Avanir's stock sells for a book value multiple of 9.7 and a sales multiple of 76, massive premiums to pharmaceutical peer averages. Of analysts following Avanir, all four advise purchasing its shares.
Bullish Scenario: Jefferies (JEF) offers a target of $10, implying the stock will more than triple.